KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Ratio (2016 - 2026)

Neogenomics filings provide 17 years of Equity Ratio readings, the most recent being 0.62 for Q1 2026.

  • On a quarterly basis, Equity Ratio rose 10.96% to 0.62 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.62, a 10.96% increase, with the full-year FY2025 number at 0.62, up 11.68% from a year prior.
  • Equity Ratio hit 0.62 in Q1 2026 for Neogenomics, roughly flat from 0.62 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.62 in Q1 2026 to a low of 0.55 in Q4 2024.
  • Median Equity Ratio over the past 5 years was 0.57 (2023), compared with a mean of 0.58.
  • Biggest five-year swings in Equity Ratio: decreased 3.85% in 2022 and later rose 11.68% in 2025.
  • Neogenomics' Equity Ratio stood at 0.57 in 2022, then decreased by 2.36% to 0.56 in 2023, then dropped by 1.64% to 0.55 in 2024, then grew by 11.68% to 0.62 in 2025, then rose by 0.05% to 0.62 in 2026.
  • The last three reported values for Equity Ratio were 0.62 (Q1 2026), 0.62 (Q4 2025), and 0.61 (Q3 2025) per Business Quant data.